文献速递前列腺癌

DNA修复基因罕见胚系致病突变与前列腺癌分级组5关系最强

Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2020-01-14

该回顾性病例对照研究纳入1694例接受根治性前列腺切除术的临床局限性前列腺癌患者,比较高级别(GG4和GG5)与低级别(GG1)患者中13个候选前列腺癌基因的胚系致病突变携带率。结果显示,高级别患者总体携带率显著高于低级别患者(8.64% vs 3.54%,p=9.98×10⁻⁶),其中ATM、BRCA2和MSH2基因关联最显著,且GG5患者携带率最高。

要点

  • 高级别前列腺癌患者胚系致病突变携带率显著高于低级别患者。
  • ATM、BRCA2和MSH2基因突变与高级别前列腺癌关联最显著。
  • GG5患者中13个基因总体突变携带率高达13.07%。

核心结论

  • 在临床局限性前列腺癌患者中,13个常检基因的胚系致病突变与GG5前列腺癌关联最强,尤其ATM、BRCA2和MSH2。

研究设计与样本

  • 回顾性病例对照研究,纳入1694例在约翰霍普金斯医院接受根治性前列腺切除术的前列腺癌患者,其中高级别(GG4和GG5)706例,低级别(GG1)988例。
  • 采用Ambry Genetics靶向下一代测序检测13个候选前列腺癌基因的胚系DNA。

主要发现

  • 高级别患者13个基因总体胚系致病突变携带率为8.64%,低级别患者为3.54%(p=9.98×10⁻⁶)。
  • ATM基因在高级别和低级别患者中的携带率分别为2.12%和0.20%(p=9.35×10⁻⁵)。
  • BRCA2基因在高级别和低级别患者中的携带率分别为2.55%和0.20%(p=8.99×10⁻⁶)。
  • MSH2基因在高级别和低级别患者中的携带率分别为0.57%和0%(p=0.03)。
  • GG5患者13个基因总体携带率为13.07%,GG1患者为3.54%(p=1.27×10⁻⁹)。

临床怎么用

  • 对高级别前列腺癌患者,尤其是GG5患者,应考虑进行胚系基因检测以指导治疗决策和家族风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rare germline mutations in several genes, primarily DNA repair genes, have been proposed to predict worse prognosis of prostate cancer (PCa). OBJECTIVE: To compare the frequency of germline pathogenic mutations in commonly assayed PCa genes between high- and low-grade PCa in patients initially presenting with clinically localized disease. DESIGN, SETTING, AND PARTICIPANTS: A retrospective case-case study of 1694 PCa patients who underwent radical prostatectomy at Johns Hopkins Hospital, including 706 patients with high-grade (grade group [GG] 4 and GG5) and 988 patients with low-grade (GG1) disease. Germline DNA was sequenced for 13 candidate PCa genes using a targeted next-generation sequencing assay by Ambry Genetics. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Carrier rates of pathogenic mutations were compared between high- and low-grade PCa patients using the Fisher's exact test. RESULTS AND LIMITATIONS: Overall, the carrier rate of germline pathogenic mutations in the 13 genes was significantly higher in high-grade patients (8.64%) than in low-grade patients (3.54%, p = 9.98 × 10-6). Individually, significantly higher carrier rates for patients with high- versus low-grade PCa were found for three genes: ATM (2.12% and 0.20%, respectively, p = 9.35 × 10-5), BRCA2 (2.55% and 0.20%, respectively, p = 8.99 × 10-6), and MSH2 (0.57% and 0%, respectively, p = 0.03). The mutation carrier rate was significantly higher in patients with GG5 than in patients with GG1 disease for the 13 genes overall (13.07% and 3.54%, respectively, p = 1.27 × 10-9); for the three genes ATM, BRCA2, and MSH2 (7.73% and 0.40%, respectively, p = 3.20 × 10-13); and for the remaining nine DNA repair genes (5.07% and 2.43%, respectively, p = 0.02). CONCLUSIONS: In men undergoing treatment for clinically localized disease, pathogenic mutations in 13 commonly assayed genes, especially ATM, BRCA2, and MSH2, are most strongly associated with GG5 PCa. These findings emphasize the importance of genetic testing in men with high-grade PCa, particularly GG5 disease, to inform both treatment decisions and familial risk assessment. PATIENT SUMMARY: Prostate cancer in men with inherited mutations in 13 commonly assayed susceptibility genes is more likely to be high-grade, high-risk disease.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wu Y, Yu H, Li S, et al. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. Eur Urol Oncol. 2020. PMID: 31948886. doi:10.1016/j.euo.2019.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。